Archive: Company News
Company News: BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins
BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a broad and comprehensive non-exclusive patent licensing agreement with CELLSCRIPT, LLC covering nucleoside-modified messenger RNA (mRNA) for use in all in vivo applications, including therapeutic and non-therapeutic applications in humans and animals.
Company News: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
– Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable solid tumors received a combination of ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody acting as a PD-1 checkpoint inhibitor.
Company News: Curetis Announces Financial Results for the First Six Months of 2017
– Further advancement of product pipeline and integration of GEAR and Gyronimo platforms
– Expansion of global installed base to 161 as of June 30, 2017; 42.5% increase over prior year
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2017, and provided an update on its financial and business guidance for the second half of 2017 and beyond.
Company News: Curetis Announces Management Board Changes
– New roles for Andreas Boos, Chris Bernard and Dr. Achim Plum
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced several changes in its Management Board, effective as of today.